MetaCap

First Tracks Biotherapeutics Earnings

NASDAQ: TRAXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

41.64-2.82 (-6.34%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

First Tracks Biotherapeutics earnings summary

In its most recent report on Nov 11, 2026 (Sep/2026), TRAX posted EPS of $-0.88 versus the $-0.92 consensus estimate, a positive surprise of 4.3%. First Tracks Biotherapeutics beat the consensus EPS estimate in 2 of the last 2 quarters, with a median surprise of +4.3%. Across the last 3 reports, TRAX shares moved an average of 5.1% (in either direction) in the first trading session after results, rising 0 times and falling 3 times.

Summary generated from market data by MetaCap's automated system. Methodology

TRAX earnings history

First Tracks Biotherapeutics reported EPS versus estimates
Report dateEPS est.EPS actualSurprisePrice reaction
Nov 11, 2026$-0.92$-0.88+4.3%-11.6%
Nov 3, 2026$-0.92$-0.88+4.3%-1.7%
Aug 12, 2026—$-0.95—-2.1%

Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.

Related